These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32214351)

  • 1. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
    PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Ye L; Xing Y; Hu J; Xi T
    Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Immunomodulatory Gallotanin-Rich Fraction From
    Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
    Front Immunol; 2020; 11():584959. PubMed ID: 33312174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
    PLOS ONE Staff
    PLoS One; 2021; 16(4):e0251020. PubMed ID: 33909703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
    Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
    Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
    Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy.
    Shang Q; Zhou S; Jiang Y; Wang D; Wang J; Song A; Luan Y
    ACS Appl Mater Interfaces; 2020 Sep; 12(36):40085-40093. PubMed ID: 32791825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
    Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
    Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
    J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCC0208018 exerts antitumor effects by activating effector T cells.
    Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
    Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
    Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
    Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
    PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
    Li C; Han X
    Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment.
    Gao Y; Duan JL; Wang CC; Yuan Y; Zhang P; Wang ZH; Sun B; Zhou J; Du X; Dang X; Bai RT; Zhang H; Xie T; Ye XY
    J Med Chem; 2024 Jul; 67(13):10848-10874. PubMed ID: 38912753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.